Eisai and Merck receive Complete Response Letter for LENVIMA/KEYTRUDA combination

Merck and partner Eisai were issued a Complete Response Letter (CRL) from regulators concerning their submission for the combination therapy of LENVIMA (lenvatinib) and KEYTRUDA (pembrolizumab).

Detected & updated continuously · Source: Nebula